Status:
COMPLETED
Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Lead Sponsor:
Visus Therapeutics
Conditions:
Presbyopia
Eligibility:
All Genders
45-80 years
Phase:
PHASE2
Brief Summary
Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
Detailed Description
A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs. Monotherapy wit...
Eligibility Criteria
Inclusion
- Male or female in good general health
- Must have presbyopia
Exclusion
- History of allergic reaction to the study drug or any of its components
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
Key Trial Info
Start Date :
March 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04774237
Start Date
March 24 2021
End Date
October 19 2021
Last Update
February 5 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Global Research Management, Inc.
Glendale, California, United States, 91204
2
Eye Research Foundation
Newport Beach, California, United States, 92663
3
Total Eye Care, PA
Memphis, Tennessee, United States, 38119